STR Highlight

Originally published to the April STR/SOR Newsletter Wed, May 01, 2019 2:55 pm

2019. Graph from Alex Duello, Evaluation Coordinator,  State Opioid Response , UMSL-MIMH

2019. Graph from Alex Duello, Evaluation Coordinator, State Opioid Response, UMSL-MIMH

In-line with STR Medication First principles, overall medication utilization significantly increased among STR episodes of care (EOCs) during the first year of the grant relative to the year prior, primarily driven by increased utilization of buprenorphine. Approximately 84% of STR EOCs involved medication compared to only 40% in the year prior to STR. Please note, the “mixed” group is composed of EOCs in which both an antagonist and agonist were prescribed. This group is highly heterogeneous and administrative data does not provide an indication of the intended treatment path. This group was created to ensure the exclusive buprenorphine and XR naltrexone groups were limited to these medications only.